Management of Acinetobacter baumannii infection in intensive care units. by Raine, R & Dheda, K
AJTCCM  VOL. 27  NO. 1  2021   5
EDITORIAL
Multidrug-resistant organisms (MDRO) are very common and 
troublesome accompaniments of treating patients in intensive care 
units. Invasive treatment modalities (endotracheal tubes, intravascular 
and urinary catheters, among others), broad-spectrum antibiotic use 
and comorbidities are major contributing factors to colonisation and 
infection. Treatment of MDRO is often very difficult.
Maasdorp et al.[1] have shown that the combination of colistin and 
tigecycline is considerably more effective in treating Acinetobacter 
baumannii (A. baumannii) infection than colistin alone in a retrospective 
cross-sectional case series. The number of patients enrolled in the study 
was small (16 in total), but there was considerably better ICU survival 
in the colistin-tigecycline treatment group (77.8%) than the colistin 
only group (28.6%), with survival to hospital discharge being 55.6% 
and 28.6%, respectively.
A. baumannii is an organism with apparent variable pathogenicity, 
implying that treatment is not always necessary. The distinction 
between colonisation (with no need for antibiotic treatment) and 
invasive infection is very important. This study excluded patients with 
colonisation on the basis of absence of fever and other markers of active 
infection. Ntusi et al.[2] reported on a cohort of patients admitted to 
the intensive care units at Groote Schuur Hospital and identified 38 
patients out 251 (15.1%) with positive cultures for A. baumannii as 
having colonisation. Bloodstream infection was present in over 70% of 
patients who died in this cohort and was an independent predictor of 
mortality.[2] Other risk factors for mortality included age, HIV-reactivity, 
low CD4 count, and multiple organ dysfunction occurring after onset 
of A. baumannii infection. Bloodstream infection was present in 44% 
of the Maasdorp cohort, but there was no apparent association with 
mortality, though this might reflect the small sample size. The challenge, 
and one that exists with many infections, is to identify patients with 
colonisation v. disease. That A. baumannii can be associated with severe 
pneumonia in a community-based setting,[3] its association with poor 
prognostic markers that are clinically meaningful, and a clear response 
to treatment in some individuals suggest that ignoring this organism, 
when identified, is an unsatisfactory approach (and which has been 
adopted by some clinicians). The identification of biomarkers that 
portend disease rather than colonisation, in large prospective studies, 
is an urgent unmet need in the field. 
Antibiotic treatment of infection is important, but is only one 
component of the complete management of MDRO infection. Measures 
to prevent the development and spread of MDRO are essential given 
the limited availability of effective antibiotics, particularly in an era 
when carbapenem-resistant enterobacteriaceae are becoming a greater 
problem than A. baumannii.
Measures to prevent the spread of MDRO were discussed in a 
previous editorial.[4] Infection prevention and control measures that are 
essential include hand-hygiene, contact precautions, patient isolation 
or cohorting, and the use of bundles for ventilator management and 
invasive procedures.[5,6] An additional issue is tracing the source 
of infection. Often this may be tracked to fomites or specific intra-
hospital locations such as casualty wards through which patients enter 
the hospital, surgical theatres, sluice room sinks etc. More studies are 
therefore required, including those using molecular fingerprinting and 
whole genome sequencing techniques[7] to investigate the epidemiology 
and trace the source of A. baumannii within hospital settings. 
In the meanwhile, strict compliance with infection prevention and 
control techniques for all intensive care units is important to attempt 
to alleviate the problem. Antimicrobial stewardship (AMS) is also 
essential. The main tenets of AMS are use of appropriate antibiotics 
in the appropriate dose for the appropriate duration, when antibiotics 
are needed.[8] This study is a small step towards identifying the right 
antibiotics but requires a much larger investigation to confirm these 
findings. More studies in Africa, and also in HIV-infected persons 
together with extended drug-susceptibility profiling of A. baumannii 
isolates, are urgently required. 
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